Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02454088 · ClinicalTrials.gov registry record · NA
A Single-Center Investigator-Initiated Evaluator-Bilateral-Comparison Pilot Study of Injectable Calcium Hydroxylapatite With and Without Triamcinolone Acetate for the Treatment of Volume Loss to Dorsum Areas of the Hands
A NA study of Volume Loss to Dorsum of Hands, sponsored by Goldman, Butterwick, Fitzpatrick and Groff.
- Completed
- Registry status
- NA
- Development phase
- 20
- Enrollment target
- 1
- Study location
NCT02454088 is a NA study of Volume Loss to Dorsum of Hands that has completed, run by Goldman, Butterwick, Fitzpatrick and Groff. The registered enrollment target is 20 participants. The trial reports 1 study location across 1 state.
The verdict
NCT02454088, a NA study of Volume Loss to Dorsum of Hands, has completed, sponsored by Goldman, Butterwick, Fitzpatrick and Groff.
- COMPLETED
- Registry status
- NA
- Development phase
- 20 participants
- Enrollment target
- 1
- Study location
Study Summary
This will be a single-center, investigator-initiated, double-blinded, randomized, bilateral-comparison pilot study of injectable Calcium hydroxylapatite with and without Triamcinolone acetate for the treatment of volume loss to the dorsum areas of the hands.
Conditions Studied
Interventions
- OTHER Calcium Hydroxylapatite and Triamcinolone acetate
- DEVICE Calcium Hydroxylapatite and Placebo
Study Locations (1)
California
- Cosmetic Laser Dermatology - San Diego
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2015-05 |
| Est. Completion | 2016-11 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02454088
The ClinicalTrials.gov registry entry for NCT02454088 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 20 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Goldman, Butterwick, Fitzpatrick and Groff, which has 18 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Volume Loss to Dorsum of Hands appearing as the primary indexed condition, and to 2 interventions - of which Calcium Hydroxylapatite and Triamcinolone acetate is the first listed.
NCT02454088 reports 1 study location spanning 1 distinct geographic area - top geographies include California.
Frequently Asked Questions
What is clinical trial NCT02454088 about?
NCT02454088 is a clinical study titled "A Single-Center Investigator-Initiated Evaluator-Bilateral-Comparison Pilot Study of Injectable Calcium Hydroxylapatite With and Without Triamcinolone Acetate for the Treatment of Volume Loss to Dorsum Areas of the Hands". This will be a single-center, investigator-initiated, double-blinded, randomized, bilateral-comparison pilot study of injectable Calcium hydroxylapatite with and without Triamcinolone acetate for the treatment of volume loss to the dorsum areas of the hands.
What is the current status of trial NCT02454088?
This trial is currently completed. It is a NA study. The enrollment target is 20 participants. The study started on 2015-05. Estimated completion is 2016-11.
What conditions does trial NCT02454088 study?
This clinical trial studies the following conditions: Volume Loss to Dorsum of Hands.
What interventions are being tested in trial NCT02454088?
The interventions under investigation include: Calcium Hydroxylapatite and Triamcinolone acetate (OTHER), Calcium Hydroxylapatite and Placebo (DEVICE).
Who is sponsoring clinical trial NCT02454088?
This trial is sponsored by Goldman, Butterwick, Fitzpatrick and Groff, which has 18 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02454088 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.